Table 1.
Participant Characteristics
| Early HIV Infection | Chronic HIV Infection | ECs | Controls | ||
|---|---|---|---|---|---|
| (n = 88) | |||||
| ART Naive | ART Treated | ||||
| Characteristic | (n = 51) | (n = 22) | (n = 66) | (n = 30) | (n = 30) |
| Age, y | |||||
| Median | 34 | 38 | 55 | 43 | 58 |
| IQR | 28–44 | 33–50 | 47–61 | 36–50 | 52–61 |
| Sex, % | |||||
| Women | 3 | 23 | 11 | 27 | 27 |
| Men | 97 | 77 | 89 | 73 | 73 |
| CD4 count, cells/µL | |||||
| Median | 460 | 220 | 595 | 576 | 821 |
| IQR | 310–640 | 35–345 | 416–700 | 498–745 | 519–1022 |
| Range | 210–1680 | 3–489 | 54–1251 | 290–1090 | 281–1173 |
| CD8 count, cells/µL | |||||
| Median | 810 | 770 | 720 | 660 | 373 |
| IQR | 620–1040 | 407–1147 | 552–968 | 433–955 | 273–536 |
| Range | 279–2590 | 54–1425 | 140–1475 | 260–1560 | 188–843 |
| CD4:CD8 ratio | |||||
| Median | 0.57 | 0.19 | 0.77 | 0.86 | 2.08 |
| IQR | 0.39–0.8 | 0.06–0.43 | 0.54–1.12 | 0.69–1.24 | 1.22–3.01 |
| Viral load, log10 copies/mL | |||||
| Median | 4.5 | 5.1 | <1.7 | <1.7 | NA |
| IQR | 3.8–5.0 | 4.4–5.5 | 1.7-1.7 | NA | |
| Range | 1.3–7.5 | 3.9–5.9 | 1.6–1.7 | NA | |
| Time to initiation of ART, y | |||||
| Median | NA | NA | 3.0 | NA | NA |
| IQR | 0.6–7.0 | ||||
| Range | 0–23.8 | ||||
| ART duration, y | |||||
| Median | NA | NA | 13.6 | NA | NA |
| IQR | 1.6–17.8 | ||||
| Range | 0.2–25.4 | ||||
Abbreviations: ART, antiretroviral therapy; ECs, elite controllers; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable.